Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma
esmo - Findings from the ZSAB-neoGOLP study
AI Summary: The ZSAB‑neoGOLP trial shows that giving a four‑drug neoadjuvant regimen—gemcitabine, oxaliplatin, lenvatinib and toripalimab—before surgery prolongs event‑free survival for patients with resectable, high‑risk intrahepatic cholangiocarcinoma. The finding suggests preoperative systemic therapy can downstage aggressive tumors and delay recurrence, potentially changing treatment sequencing for this challenging disease.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 5 wks
Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 5 wks
Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 6 wks
Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 7 wks
Romiplostim reduces chemotherapy‑induced thrombocytopenia and prevents recurrence / 2 months
Daraxonrasib improves survival versus chemotherapy in metastatic pancreatic cancer / 4 hrs
DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 36 hrs
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Avian Influenza, Weight Loss, Health IT, Cybersecurity and look for the RSS link.
StackHealth Time Machine